Ian M. Thompson

发表

Association of African-American ethnic background with survival in men with metastatic prostate cancer.

I. Thompson, C. Tangen, E. Crawford, 2001, Journal of the National Cancer Institute.

Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.

P. Goodman, C. Tangen, D. Ankerst, 2013, Urology.

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

C. Tangen, C. Higano, E. Small, 2012, The Journal of urology.

Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association.

J. Oesterling, M. Resnick, I. Thompson, 1995, The Journal of urology.

Finasteride decreases the risk of prostatic intraepithelial neoplasia.

I. Thompson, M. Lucia, H. Parnes, 2007, The Journal of urology.

The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.

Sudhir Srivastava, William E Grizzle, O John Semmes, 2004, Urologic oncology.

Chemoprevention of prostate cancer.

P. Goodman, C. Tangen, M. Lucia, 1994, The Journal of urology.

Chemoprevention of prostate cancer.

I. Thompson, E. Canby-Hagino, O. Brawley, 1994, Urology.

Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial

I. Thompson, P. Goodman, C. Tangen, 2008, The Prostate.